← 返回

一种高效的无饲养层且化学成分明确的扩增策略用于高度纯化的人脐带血来源 NK 细胞

英文原题:An efficient feeder-free and chemically-defined expansion strategy for highly purified natural killer cells derived from human cord blood.

查看英文原题

An efficient feeder-free and chemically-defined expansion strategy for highly purified natural killer cells derived from human cord blood.

PubMed 2023/06/01(内容时间) Regen Ther Q2 · IF 4(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

我们建立的無饲养层扩增系统从人脐带血中获得了大规模、高度纯化且具有细胞毒性的 NKC。该系统提供了临床级即用型 NKC 的稳定供应,并可能适用于基于同种异体 NKC 的癌症免疫治疗,包括 GBM。

研究思路结论见上方概要

NK 细胞(NKC)是一种免疫细胞,无需预先致敏即可通过直接识别配体攻击癌细胞。脐带血来源的NKC(CBNKC)是同种异体NKC肿瘤免疫治疗中一种有前景的工具。高效的NKC扩增和减少T细胞混杂对于同种异体NKC免疫治疗在不诱导移植物抗宿主反应的情况下取得成功至关重要。我们此前建立了一种高效的外体扩增系统,由来源于人外周血的高度纯化NKC组成。在此,我们评估了该NKC扩增系统使用CB时的性能,并对扩增后的细胞群体进行了表征。

冻存的CB单个核细胞(CBMCs)去除T细胞后,在固定化抗NKp46和抗CD16抗体条件下,与重组人白细胞介素(rhIL)-18和rhIL-2共培养。在扩增7、14和21天后,评估NK细胞的纯度、扩增倍数以及NK激活性和抑制性受体的表达水平。同时检测这些NK细胞抑制T98G生长的能力,T98G是一种对NK活性敏感的胶质母细胞瘤(GBM)细胞系。

所有扩增的T细胞去除的CBMC在扩增7天、14天和21天时分别有超过80%、98%和99%包含CD3-CD56+NKC。扩增的CBNKC表达NK活化受体LFA-1、NKG2D、DNAM-1、NKp30、NKp44、NKp46、FcγRIII以及NK抑制性受体TIM-3、TIGIT、TACTILE、NKG2A。三个扩增的CBNKC中有两个弱表达PD-1,但随扩增时间逐渐表达PD-1。三个扩增的CBNKC中有一个在扩增期间几乎不表达PD-1。LAG-3表达在供者间存在差异,扩增期间未发现一致的变化。所有扩增的CBNKC均对T98G细胞表现出明显的细胞毒性介导的生长抑制。细胞毒性水平随扩增时间延长而逐渐降低。

展开英文摘要原文

Frozen CB mononuclear cells (CBMCs), with T cells removed, were cultured with recombinant human interleukin (rhIL)-18 and rhIL-2 under conditions where anti-NKp46 and anti-CD16 antibodies were immobilized. Following 7, 14, and 21 days of expansion, the purity, fold-expansion rates of NKCs, and the expression levels of NK activating and inhibitory receptors were assessed. The ability of these NKCs to inhibit the growth of T98G, a glioblastoma (GBM) cell line sensitive to NK activity, was also examined.

All expanded T cell-depleted CBMCs were included in over 80%, 98%, and 99% of CD3 - CD56 + NKCs at 7, 14, and 21 days of expansion, respectively. The NK activating receptors LFA-1, NKG2D, DNAM-1, NKp30, NKp44, NKp46, FcγRIII and NK inhibitory receptors TIM-3, TIGIT, TACTILE, NKG2A were expressed on the expanded-CBNKCs. Two out of three of the expanded-CBNKCs weakly expressed PD-1, yet gradually expressed PD-1 according to expansion period. One of the three expanded CBNKCs almost lacked PD-1 expression during the expansion period. LAG-3 expression was variable among donors, and no consistent changes were identified during the expansion period. All of the expanded CBNKCs elicited distinct cytotoxicity-mediated growth inhibition on T98G cells. The level of cytotoxicity was gradually decreased based on the prolonged expansion period.

Our established feeder-free expansion system yielded large scale highly purified and cytotoxic NKCs derived from human CB. The system provides a stable supply of clinical grade off-the-shelf NKCs and may be feasible for allogeneic NKC-based immunotherapy for cancers, including GBM.

论文信息

作者
Nakazawa T、Maeoka R、Morimoto T、Matsuda R、Nakamura M、Nishimura F、Yamada S、Nakagawa I
单位
Grandsoul Research Institute for Immunology, Inc., Uda, Nara, 633-2221, Japan.Japan
期刊
Regenerative therapy2023 Dec
原文标识
PubMed 37303464 · DOI 10.1016/j.reth.2023.05.006